New drug combo shows promise in myeloma stem cell transplant
NCT ID NCT04680468
First seen Dec 15, 2025 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tests whether adding the drug belantamab mafodotin before and after a stem cell transplant can improve outcomes for people with multiple myeloma. About 41 participants will receive the drug alongside standard treatments. The main goal is to see if more patients achieve a deep remission (no detectable cancer) one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.